Candel Therapeutics Secures $100 Million Funding to Accelerate Immunotherapy Pipeline

Candel Therapeutics, a clinical-stage biopharmaceutical innovator specializing in multimodal biological immunotherapies, has successfully completed a public offering of 18.35 million common shares at $5.45 per share, generating $100 million in capital. The funding round closed in late February 2026, with underwriters granted a 30-day option to purchase an additional 2.75 million shares worth $15 million under identical terms. Despite the capital raise, Candel’s stock experienced initial market volatility, trading down 11.76% to $5.25 on announcement but recovering to $5.95 by Thursday’s close, reflecting broader market sentiment around biotech financing activities.

Strategic Financing Advances Candel’s Multimodal Immunotherapy Programs

The proceeds from this financing will fuel critical commercial readiness activities for aglatimagene besadenovec (internally designated CAN-2409), Candel’s flagship immunotherapy candidate targeting early-stage, localized prostate cancer. Beyond commercialization efforts, the capital will support ongoing phase 3 clinical development of aglatimagene in non-small cell lung cancer (NSCLC) and general corporate operations. Candel has built two distinct technology platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, positioning the company with a diversified portfolio of clinical-stage candidates.

FDA Recognition Bolsters Candel’s Clinical Standing

Aglatimagene has received significant regulatory backing from the FDA, securing Fast Track Designation for NSCLC treatment and both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) Designations for localized prostate cancer in intermediate- to high-risk patient populations. The company’s broader pipeline reflects encouraging clinical progress: phase 2a trials of aglatimagene demonstrated promising results in both NSCLC and pancreatic ductal adenocarcinoma (PDAC), with the lead indication successfully completing a placebo-controlled phase 3 trial in prostate cancer. Candel’s second platform candidate, Linoserpaturev, is advancing through phase 1b studies in recurrent high-grade glioma, while aglatimagene also earned Orphan Drug Designation for PDAC applications.

Underwriters and Market Context

Citigroup, Cantor, and Stifel are serving as joint bookrunning managers, with LifeSci Capital functioning as lead manager for the offering. Over the past 52 weeks, Candel shares have ranged from $4.25 to $13.68, reflecting typical volatility observed in clinical-stage biotechnology equities during development and financing milestones.